Drug intelligence / Profile preview

ExoLiquid

Development stage: Preclinical
Lead developer: EVMed
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

ExoLiquid is a proprietary exosome-based product developed by EVMed Group, characterized by its liquid formulation. It is designed for a broad range of applications, including both therapeutics and diagnostics. The product is part of EVMed's suite of exosome technologies, which includes platforms for isolation (ExoPure), characterization (ExoTest), and specialized applications (ExoPlus, ExoCell). While specific molecular targets and clinical indications are not disclosed in general corporate literature, ExoLiquid serves as a vehicle for delivering proteins, nucleic acids, or other bioactive molecules, or as a medium for identifying exosomal biomarkers in clinical samples.

Brand names: ExoLiquid
Other names: ExoLiquid-EVMed

Beyond the preview

Go deeper on ExoLiquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoLiquid.

Explore the full profile